5 February 2021
SLAUGHTER AND MAY IS ADVISING GW PHARMACEUTICALS ON ITS RECOMMENDED CASH AND SHARE ACQUISITION BY JAZZ PHARMACEUTICALS
Advising firms
Deal team
4 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| George Schoen Lead | Cravath, Swaine & Moore LLP | Not stated | Not stated | Not stated |
| Damien Zoubek Lead | Cravath, Swaine & Moore LLP | Not stated | Not stated | Not stated |
| Jenny Hochenberg Lead | Cravath, Swaine & Moore LLP | Not stated | Not stated | Not stated |
| Doug Snyder | Not stated | Not stated | Not stated | Not stated |
1 more lawyer on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 7.20bn ($7.2 billion)
- What the figure measures
- Total transaction value
- Client
- GW Pharmaceuticals plcTarget
- Counterparties
- Jazz Pharmaceuticals plc (Buy-side)